Tumor-specific alterations, cellular metabolism, chromatin landscape and availability of other specific transcription factors are likely to also affect mutant p53 activities (Adorno et al, 2009; Dell’Orso et al, 2011; Haupt et al, 2009; Kim and Deppert, 2003, 2004; Li et al, 2008; Rodriguez et al, 2012; Strano et al, 2007). Here, TP53 is linked to neoplasm.